From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib

Sunitinib induces genomic instability of renal carcinoma cells through affecting the interaction of LC3-II and PARP-1

(2017) Siyuan Yan et al.   Cell Death & Disease

A role for ABCG2 beyond drug transport: Regulation of autophagy

(2016) Rui Ding et al.   Autophagy

Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA

(2016) Le Qu et al.   CANCER CELL

The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries

(2016) Amal Kamal Abdel-Aziz et al.   EXPERIMENTAL NEUROLOGY

Dual modulation of MCL-1 and mTOR determines the response to sunitinib

(2016) Mohamed Elgendy et al.   JOURNAL OF CLINICAL INVESTIGATION

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth

(2016) Maria Rovithi et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy

(2016) Néstor Prieto-Domínguez et al.   JOURNAL OF PINEAL RESEARCH

Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents

(2016) Marwa A. Aziz et al.   Scientific Reports

Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021

(2016) Cynthia Wetmore et al.   Cancer Medicine

Metabolic, autophagic, and mitophagic activities in cancer initiation and progression

(2016) Anita Hjelmeland et al.   Biomedical Journal

Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma

(2015) Nicola Mitchell et al.   Asia-Pacific Journal of Clinical Oncology

Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux

(2015) Sandy Giuliano et al.   Autophagy

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers

(2015) C Wu et al.   BRITISH JOURNAL OF CANCER

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma

(2015) Elizabeth I. Buchbinder et al.   CANCER

Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside

(2015) Chiara Alessandra Cella et al.   CANCER TREATMENT REVIEWS

Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells

(2015) Hiromi Sato et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability

(2015) D-W Wu et al.   ONCOGENE

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

(2015) L Zhou et al.   ONCOGENE

Modulation of Imatinib Cytotoxicity by Selenite in HCT116 Colorectal Cancer Cells

(2014) Amal Kamal Abdel-Aziz et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries

(2014) Amal Kamal Abdel-Aziz et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications

(2014) R. Adelaiye et al.   MOLECULAR CANCER THERAPEUTICS

Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner

(2014) Mohamed Elgendy et al.   Nature Communications

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells

(2013) M Santoni et al.   BRITISH JOURNAL OF CANCER

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

(2013) Petros D. Grivas et al.   CANCER

Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer

(2013) Xian Li et al.   CANCER LETTERS

Sphingosine Kinase-1 Activation Causes Acquired Resistance Against Sunitinib in Renal Cell Carcinoma Cells

(2013) Hui Gao et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Synergistic Cooperation Between Sunitinib and Cisplatin Promotes Apoptotic Cell Death in Human Medullary Thyroid Cancer

(2013) Alessia Lopergolo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells

(2013) Ying Liu et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells

(2012) Chieh-Lin Jerry Teng et al.   ANNALS OF HEMATOLOGY

Sunitinib malate in solitary fibrous tumor (SFT)

(2012) S. Stacchiotti et al.   ANNALS OF ONCOLOGY

Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients

(2012) A. W. Griffioen et al.   CLINICAL CANCER RESEARCH

Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines

(2012) Annamaria Piscazzi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Inhibition of Autophagy Enhances Sunitinib-Induced Cytotoxicity in Rat Pheochromocytoma PC12 cells

(2012) Tatsuhiko Ikeda et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer

(2012) Ji-Youn Han et al.   LUNG CANCER

Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells

(2012) P. B. Makhov et al.   MOLECULAR CANCER THERAPEUTICS

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer

(2012) Chi-Iou Lin et al.   SURGERY

Autophagy modulation for cancer therapy

(2011) Zhineng J. Yang et al.   CANCER BIOLOGY & THERAPY

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

(2011) James Finke et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer

(2011) Bryan J. Schneider et al.   Journal of Thoracic Oncology

Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1α synthesis in HT-29 colon cancer cells

(2010) Hyun-Woo Shin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH

The autophagic tumor stroma model of cancer or “battery-operated tumor growth”

(2010) Ubaldo E. Martinez-Outschoorn et al.   CELL CYCLE

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

(2010) Ana M. Molina et al.   INVESTIGATIONAL NEW DRUGS

Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways

(2010) F. Yang et al.   MOLECULAR CANCER RESEARCH

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

(2010) H. J. Hammers et al.   MOLECULAR CANCER THERAPEUTICS

Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

(2010) D. Koeberle et al.   ONCOLOGIST

Autophagy plays an important role in Sunitinib-mediated cell death in H9c2 cardiac muscle cells

(2010) Yuqin Zhao et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Phase II study of sunitinib in men with advanced prostate cancer

(2009) M. Dror Michaelson et al.   ANNALS OF ONCOLOGY

Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

(2009) Sonja Loges et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2

(2009) Chun-ling Dai et al.   CANCER LETTERS

Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase

(2009) Risto Kerkela et al.   CTS-Clinical and Translational Science

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

(2009) Darren R. Feldman et al.   INVESTIGATIONAL NEW DRUGS

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

(2009) Suzanne George et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

(2008) S. Shukla et al.   DRUG METABOLISM AND DISPOSITION

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY